DAWN · Insider Trading

Day One Biopharmaceuticals, Inc. Common Stock

Every open-market purchase and sale reported by DAWN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
0
code P
Sales
0
code S
Reporting Insiders
1
current holders
DAWN — Recent Form 4 Transactions (latest 2026-04-23)
FiledInsiderRole TypeSharesValue
2026-04-23 William Grossman Director D −136,495 deriv. —
2026-04-23 Habib J Dable Director D −136,495 deriv. —
2026-04-23 Lauren Merendino Chief Commercial Officer D −60,157 —
2026-04-23 Michael Vasconcelles Head of Research and Dev. D −4,397 —
2026-04-23 J. Scott Garland Director D −184,107 deriv. —
2026-04-23 Garry A Nicholson Director D −141,235 deriv. —
2026-04-23 Adam Dubow Gen Counsel & Secretary D −72,694 —
2026-04-23 Charles N York II COO and CFO D −312,025 —
2026-04-23 Natalie C. Holles Director D −57,310 —
2026-04-23 Jeremy Bender CHIEF EXECUTIVE OFFICER D −1,799,031 —
2026-04-23 John A. Josey Director D −72,292 —
2026-04-23 Saira Ramasastry Director D −40,485 —
2026-02-18 Charles N York II COO and CFO MIXED +17,310 −$70.36K
2026-02-18 Michael Vasconcelles Head of Research and Dev. MIXED +4,397 −$31.65K
2026-02-18 Adam Dubow Gen Counsel & Secretary MIXED +10,068 −$74.19K
2026-02-18 Lauren Merendino Chief Commercial Officer MIXED +9,348 −$67.45K
2026-02-18 Jeremy Bender CHIEF EXECUTIVE OFFICER MIXED +27,478 −$179.34K
2026-01-30 Charles N York II COO and CFO A +314,000 deriv. —
2026-01-30 Adam Dubow Gen Counsel & Secretary A +175,000 deriv. —
2026-01-30 Lauren Merendino Chief Commercial Officer A +184,000 deriv. —
2026-01-30 Michael Vasconcelles Head of Research and Dev. A +285,000 deriv. —
2026-01-30 Jeremy Bender CHIEF EXECUTIVE OFFICER A +592,000 deriv. —
2025-11-26 Jeremy Bender CHIEF EXECUTIVE OFFICER G −14,450 —
2025-11-18 Jeremy Bender CHIEF EXECUTIVE OFFICER MIXED +15,800 −$141.69K
2025-11-18 Lauren Merendino Chief Commercial Officer MIXED +6,810 −$33.22K
2025-11-18 Charles N York II COO and CFO MIXED +12,813 −$36.21K
2025-11-18 Adam Dubow Gen Counsel & Secretary MIXED +7,768 −$38.50K
2025-11-07 Adam Dubow Gen Counsel & Secretary MIXED +309,000 deriv. —
2025-11-07 John A. Josey Director MIXED — —
2025-11-07 J. Scott Garland Director MIXED — —
2025-11-07 Habib J Dable Director MIXED — —
2025-11-07 Jeremy Bender CHIEF EXECUTIVE OFFICER MIXED — —
2025-11-07 Natalie C. Holles Director MIXED — —
2025-11-07 Saira Ramasastry Director MIXED — —
2025-11-07 William Grossman Director MIXED — —
2025-11-07 Lauren Merendino Chief Commercial Officer MIXED — —
2025-11-07 Charles N York II COO and CFO MIXED — —
2025-11-07 Garry A Nicholson Director MIXED — —
2025-08-19 Lauren Merendino Chief Commercial Officer MIXED +6,770 −$25.48K
2025-08-19 Adam Dubow Gen Counsel & Secretary MIXED +7,722 −$29.54K
2025-08-19 Jeremy Bender CHIEF EXECUTIVE OFFICER MIXED +15,628 −$108.67K
2025-08-19 Charles N York II COO and CFO MIXED +12,769 −$27.79K
2025-07-14 Jeremy Bender CHIEF EXECUTIVE OFFICER G — —
2025-06-18 Michael Vasconcelles Head of Research and Dev. A +572,000 deriv. —
2025-06-04 Saira Ramasastry Director A +37,500 deriv. —
2025-06-04 J. Scott Garland Director A +37,500 deriv. —
2025-06-04 Natalie C. Holles Director A +37,500 deriv. —
2025-06-04 John A. Josey Director A +37,500 deriv. —
2025-06-04 Garry A Nicholson Director A +37,500 deriv. —
2025-06-04 Habib J Dable Director A +37,500 deriv. —
DAWN — Current Insider Holders
InsiderRole Shares HeldValue
Samuel C. Blackman HEAD OF R&D 2,034,015 $43.79M
DAWN Insider Trading FAQ
Who are the insiders at DAWN?
1 officers, directors and 10%+ beneficial owners currently report holdings in DAWN via SEC Form 4.
Are DAWN insiders buying or selling?
Across the 50 most recent Form 4 filings for DAWN, 0 were open-market purchases (code P) and 0 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is DAWN insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent DAWN filing is dated 2026-04-23.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the DAWN quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.